Integrating Novel Personalized Therapy into the
Non-Small Cell Lung Cancer Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AstraZeneca and Lilly USA, LLC

Lung cancer is by far the leading cause of cancer death among both men and women and more people die of lung cancer than of colon, breast, and prostate cancers combined. Recent clinical data have demonstrated that NSCLC is a very heterogeneous disease. However, as more comprehensive information has been gathered regarding tumor characterization, treatment modalities for NSCLC have expanded to include agents with more specific targets. The use of histologic subtypes and molecular biomarker assessment in NSCLC has resulted in therapeutic paradigms that can be optimized for individual patients based on unique characteristics of their cancer. Additionally, more agents that have been recently approved could help increase prognosis and quality of life in NSCLC patients. Guidelines from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have recently been updated to incorporate a section on maintenance therapy in the management of advanced NSCLC. Maintenance therapy refers to treatment that prevents a cancer from spreading after it has responded to initial treatments and has been shown to extend the lives of advanced NSCLC patients.

Upon Completion of this activity, participants will be able to:

  • Examine safety, efficacy and tolerability data and outcomes in current and emerging treatments in the management of advanced NSCLC

  • Analyze recent clinical data and updated strategies on novel therapies for patients with advanced squamous NSCLC

  • Review the rationale for continued histologic subtyping and biomarker analysis in patients with advanced NSCLC before treatment initiation

  • Assess patient and clinical factors used to individualize therapy and guide first-line and maintenance therapy selection in advanced NSCLC

  • Explore new treatment options for patients who have metastatic NSCLC with disease progression

  • Discuss considerations for determining appropriate maintenance therapy, including selection of continuation versus switch maintenance in NSCLC treatment

Faculty: Joel Neal, MD, PhD
Assistant Professor of Medicine Stanford University Medical Center


Dr. Neal serves on an advisory board or panel for ARIAD Pharmaceuticals, ARMO BioSciences, Boehringer lngelheim, CARET, Clovis Oncology and Nektar; he receives research support from ARIAD Pharmaceuticals, ArQuie, Boehringer lngelheim, Exelixis, Genentech/Roche, Merck and Novartis. He will be discussing unlabeled/investigational uses of afatinab and osimertinib. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by educational grants from
AstraZeneca and Lilly USA, LLC

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue